Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

First family case of haemoglobinopathy Titusville in France and literature overview.

Ruetsch C, Raffort J, Panaia-Ferrari P, Deconde C, Caruba-Bafghi C, Naimi M, Kavafyan J, Suissa L, Chinetti G.

J Clin Pathol. 2019 Jul;72(7):501-505. doi: 10.1136/jclinpath-2018-205616. Epub 2019 Apr 2. Review. Erratum in: J Clin Pathol. 2019 Jul 15;:.

PMID:
30940650
2.

Differential micro-RNA expression in diabetic patients with abdominal aortic aneurysm.

Lareyre F, Clément M, Moratal C, Loyer X, Jean-Baptiste E, Hassen-Khodja R, Chinetti G, Mallat Z, Raffort J.

Biochimie. 2019 Jul;162:1-7. doi: 10.1016/j.biochi.2019.03.012. Epub 2019 Mar 26.

PMID:
30922869
3.

Transforming growth factor β neutralization finely tunes macrophage phenotype in elastase-induced abdominal aortic aneurysm and is associated with an increase of arginase 1 expression in the aorta.

Raffort J, Lareyre F, Clément M, Moratal C, Jean-Baptiste E, Hassen-Khodja R, Burel-Vandenbos F, Bruneval P, Chinetti G, Mallat Z.

J Vasc Surg. 2019 Feb 18. pii: S0741-5214(18)32305-X. doi: 10.1016/j.jvs.2018.09.045. [Epub ahead of print]

PMID:
30792060
4.

Regarding "Outcomes associated with hyperglycemia after abdominal aortic aneurysm repair".

Lareyre F, Chinetti G, Raffort J.

J Vasc Surg. 2019 Jan;69(1):310. doi: 10.1016/j.jvs.2018.10.048. No abstract available.

PMID:
30579453
5.

Regarding "Diabetes-Related Factors and Abdominal Aortic Aneurysm Events: The Atherosclerotic Risk in Communities Study".

Raffort J, Chinetti G, Lareyre F.

Ann Epidemiol. 2019 Mar;31:75-76. doi: 10.1016/j.annepidem.2018.11.004. Epub 2018 Nov 12. No abstract available.

PMID:
30482433
6.

IL-1β- and IL-4-polarized macrophages have opposite effects on adipogenesis of intramuscular fibro-adipogenic progenitors in humans.

Moratal C, Raffort J, Arrighi N, Rekima S, Schaub S, Dechesne CA, Chinetti G, Dani C.

Sci Rep. 2018 Nov 19;8(1):17005. doi: 10.1038/s41598-018-35429-w.

7.

Association of abdominal aortic aneurysm diameter with insulin resistance index.

Lareyre F, Moratal C, Zereg E, Carboni J, Panaïa-Ferrari P, Bayer P, Jean-Baptiste E, Hassen-Khodja R, Chinetti G, Raffort J.

Biochem Med (Zagreb). 2018 Oct 15;28(3):030702. doi: 10.11613/BM.2018.030702.

8.

Glucagon-Like peptide-1: A new therapeutic target to treat abdominal aortic aneurysm?

Raffort J, Chinetti G, Lareyre F.

Biochimie. 2018 Sep;152:149-154. doi: 10.1016/j.biochi.2018.06.026. Epub 2018 Jul 3. Review.

PMID:
30103898
9.

Diabetes and aortic aneurysm: current state of the art.

Raffort J, Lareyre F, Clément M, Hassen-Khodja R, Chinetti G, Mallat Z.

Cardiovasc Res. 2018 Nov 1;114(13):1702-1713. doi: 10.1093/cvr/cvy174.

10.

Investigation of Plasma Inflammatory Profile in Diabetic Patients With Abdominal Aortic Aneurysm: A Pilot Study.

Lareyre F, Moratal C, Chikande J, Jean-Baptiste E, Hassen-Khodja R, Neels J, Chinetti G, Raffort J.

Vasc Endovascular Surg. 2018 Nov;52(8):597-601. doi: 10.1177/1538574418784717. Epub 2018 Jun 25.

PMID:
29940819
11.

Insights on glicentin, a promising peptide of the proglucagon family.

Raffort J, Lareyre F, Massalou D, Fénichel P, Panaïa-Ferrari P, Chinetti G.

Biochem Med (Zagreb). 2017 Jun 15;27(2):308-324. doi: 10.11613/BM.2017.034. Review.

12.

Decreased serum glicentin concentration in patients with severe and morbid obesity.

Raffort J, Panaïa-Ferrari P, Lareyre F, Blois M, Bayer P, Staccini P, Fénichel P, Chinetti G.

Ann Clin Biochem. 2018 Mar;55(2):198-204. doi: 10.1177/0004563217700172. Epub 2017 Jun 29.

PMID:
28661200
13.

Monocytes and macrophages in abdominal aortic aneurysm.

Raffort J, Lareyre F, Clément M, Hassen-Khodja R, Chinetti G, Mallat Z.

Nat Rev Cardiol. 2017 Aug;14(8):457-471. doi: 10.1038/nrcardio.2017.52. Epub 2017 Apr 13. Review.

PMID:
28406184
14.

Fasting Circulating Glicentin Increases After Bariatric Surgery.

Raffort J, Panaïa-Ferrari P, Lareyre F, Bayer P, Staccini P, Fénichel P, Chinetti G.

Obes Surg. 2017 Jun;27(6):1581-1588. doi: 10.1007/s11695-016-2493-5.

15.

Erratum: The kynurenine pathway is activated in human obesity and shifted toward kynurenine monooxygenase activation.

Favennec M, Hennart B, Caiazzo R, Leloire A, Yengo L, Verbanck M, Arredouani A, Marre M, Pigeyre M, Bessede A, Guillemin GJ, Chinetti G, Staels B, Pattou F, Balkau B, Allorge D, Froguel P, Poulain-Godefroy O.

Obesity (Silver Spring). 2016 Aug;24(8):1821. doi: 10.1002/oby.21593. No abstract available.

16.

The kynurenine pathway is activated in human obesity and shifted toward kynurenine monooxygenase activation.

Favennec M, Hennart B, Caiazzo R, Leloire A, Yengo L, Verbanck M, Arredouani A, Marre M, Pigeyre M, Bessede A, Guillemin GJ, Chinetti G, Staels B, Pattou F, Balkau B, Allorge D, Froguel P, Poulain-Godefroy O.

Obesity (Silver Spring). 2015 Oct;23(10):2066-74. doi: 10.1002/oby.21199. Epub 2015 Sep 8. Erratum in: Obesity (Silver Spring). 2016 Aug;24(8):1821.

17.

Structural and functional changes in HDL with low grade and chronic inflammation.

O'Neill F, Riwanto M, Charakida M, Colin S, Manz J, McLoughlin E, Khan T, Klein N, Kay CW, Patel K, Chinetti G, Staels B, D'Aiuto F, Landmesser U, Deanfield J.

Int J Cardiol. 2015 Jun 1;188:111-6. doi: 10.1016/j.ijcard.2015.03.058. Epub 2015 Mar 5.

PMID:
25919891
18.

Von Willebrand factor as a biological sensor of blood flow to monitor percutaneous aortic valve interventions.

Van Belle E, Rauch A, Vincentelli A, Jeanpierre E, Legendre P, Juthier F, Hurt C, Banfi C, Rousse N, Godier A, Caron C, Elkalioubie A, Corseaux D, Dupont A, Zawadzki C, Delhaye C, Mouquet F, Schurtz G, Deplanque D, Chinetti G, Staels B, Goudemand J, Jude B, Lenting PJ, Susen S.

Circ Res. 2015 Mar 27;116(7):1193-201. doi: 10.1161/CIRCRESAHA.116.305046. Epub 2015 Feb 10.

PMID:
25670067
19.

Activation of intestinal peroxisome proliferator-activated receptor-α increases high-density lipoprotein production.

Colin S, Briand O, Touche V, Wouters K, Baron M, Pattou F, Hanf R, Tailleux A, Chinetti G, Staels B, Lestavel S.

Eur Heart J. 2013 Aug;34(32):2566-74. doi: 10.1093/eurheartj/ehs227. Epub 2012 Jul 26.

20.

Nur77turing macrophages in atherosclerosis.

Lefebvre P, Chinetti G, Staels B.

Circ Res. 2012 Feb 3;110(3):375-7. doi: 10.1161/CIRCRESAHA.111.263178. No abstract available.

PMID:
22302751
21.

Association between a thyroid hormone receptor-α gene polymorphism and blood pressure but not with coronary heart disease risk.

Goumidi L, Gauthier K, Legry V, Mayi TH, Houzet A, Cottel D, Montaye M, Proust C, Kee F, Ferrières J, Arveiler D, Ducimetière P, Staels B, Dallongeville J, Chinetti G, Flamant F, Amouyel P, Meirhaeghe A.

Am J Hypertens. 2011 Sep;24(9):1027-34. doi: 10.1038/ajh.2011.94. Epub 2011 Jun 9.

PMID:
21654857
22.

PPARs/RXRs in Cardiovascular Physiology and Disease.

Finck BN, Chinetti G, Staels B.

PPAR Res. 2008;2008:173780. doi: 10.1155/2008/173780. No abstract available.

23.

Association between liver X receptor alpha gene polymorphisms and risk of metabolic syndrome in French populations.

Legry V, Cottel D, Ferrières J, Chinetti G, Deroide T, Staels B, Amouyel P, Meirhaeghe A.

Int J Obes (Lond). 2008 Mar;32(3):421-8. doi: 10.1038/sj.ijo.0803705. Epub 2008 Jan 22.

PMID:
18209740
24.

Transcriptional regulation of macrophage cholesterol trafficking by PPARalpha and LXR.

Chinetti G, Fruchart JC, Staels B.

Biochem Soc Trans. 2006 Dec;34(Pt 6):1128-31. Review. Erratum in: Biochem Soc Trans. 2007 Feb;35(Pt 1):165.

PMID:
17073767
25.

[Inflammation and metabolic and vascular diseases: pharmacologic approaches].

Chinetti G, Staels B.

Journ Annu Diabetol Hotel Dieu. 2006:153-8. Review. French. No abstract available.

PMID:
17051858
26.

Fibrates.

Robillard R, Fontaine C, Chinetti G, Fruchart JC, Staels B.

Handb Exp Pharmacol. 2005;(170):389-406. Review.

PMID:
16596808
27.

Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis.

Lefebvre P, Chinetti G, Fruchart JC, Staels B.

J Clin Invest. 2006 Mar;116(3):571-80. Review.

28.

Genes of cholesterol metabolism in human atheroma: overexpression of perilipin and genes promoting cholesterol storage and repression of ABCA1 expression.

Forcheron F, Legedz L, Chinetti G, Feugier P, Letexier D, Bricca G, Beylot M.

Arterioscler Thromb Vasc Biol. 2005 Aug;25(8):1711-7. Epub 2005 Jun 16.

PMID:
15961705
29.

Peroxisome proliferator-activated receptor alpha induces NADPH oxidase activity in macrophages, leading to the generation of LDL with PPAR-alpha activation properties.

Teissier E, Nohara A, Chinetti G, Paumelle R, Cariou B, Fruchart JC, Brandes RP, Shah A, Staels B.

Circ Res. 2004 Dec 10;95(12):1174-82. Epub 2004 Nov 11.

PMID:
15539630
30.

Ala12Ala genotype of the peroxisome proliferator-activated receptor gamma2 protects against atherosclerosis.

Temelkova-Kurktschiev T, Hanefeld M, Chinetti G, Zawadzki C, Haulon S, Kubaszek A, Koehler C, Leonhardt W, Staels B, Laakso M.

J Clin Endocrinol Metab. 2004 Sep;89(9):4238-42.

PMID:
15356014
31.

Expression of adiponectin receptors in human macrophages and regulation by agonists of the nuclear receptors PPARalpha, PPARgamma, and LXR.

Chinetti G, Zawadski C, Fruchart JC, Staels B.

Biochem Biophys Res Commun. 2004 Jan 30;314(1):151-8.

PMID:
14715259
32.

Peroxisome proliferator-activated receptors and inflammation: from basic science to clinical applications.

Chinetti G, Fruchart JC, Staels B.

Int J Obes Relat Metab Disord. 2003 Dec;27 Suppl 3:S41-5. Review.

PMID:
14704743
33.
34.
35.

Rupture of the atherosclerotic plaque: does a good animal model exist?

Cullen P, Baetta R, Bellosta S, Bernini F, Chinetti G, Cignarella A, von Eckardstein A, Exley A, Goddard M, Hofker M, Hurt-Camejo E, Kanters E, Kovanen P, Lorkowski S, McPheat W, Pentikäinen M, Rauterberg J, Ritchie A, Staels B, Weitkamp B, de Winther M; MAFAPS Consortium.

Arterioscler Thromb Vasc Biol. 2003 Apr 1;23(4):535-42. Epub 2003 Feb 6. Review.

36.

Peroxisome proliferator-activated receptor (PPAR) alpha and PPARbeta/delta, but not PPARgamma, modulate the expression of genes involved in cardiac lipid metabolism.

Gilde AJ, van der Lee KA, Willemsen PH, Chinetti G, van der Leij FR, van der Vusse GJ, Staels B, van Bilsen M.

Circ Res. 2003 Mar 21;92(5):518-24. Epub 2003 Feb 6.

PMID:
12600885
37.

Peroxisome proliferator-activated receptor alpha reduces cholesterol esterification in macrophages.

Chinetti G, Lestavel S, Fruchart JC, Clavey V, Staels B.

Circ Res. 2003 Feb 7;92(2):212-7.

PMID:
12574149
38.

The role of PPARs in atherosclerosis.

Duval C, Chinetti G, Trottein F, Fruchart JC, Staels B.

Trends Mol Med. 2002 Sep;8(9):422-30. Review.

PMID:
12223313
39.

[Role of the peroxisome proliferator-activated receptors (PPARS) in the regulation of lipids and inflammation control].

Bocher V, Chinetti G, Fruchart JC, Staels B.

J Soc Biol. 2002;196(1):47-52. Review. French.

PMID:
12134632
40.

Macrophage function and stability of the atherosclerotic plaque: progress report of a European project.

Bellosta S, Bernini F, Chinetti G, Cignarella A, Cullen P, von Eckardstein A, Exley A, Freeth J, Goddard M, Hofker M, Kanters E, Kovanen P, Lorkowski S, Pentikäinen M, Printen J, Rauterberg J, Ritchie A, Staels B, Weitkamp B, de Winther M; Macrophage Function and Stability of Atherosclerotic Plaque Consortium.

Nutr Metab Cardiovasc Dis. 2002 Feb;12(1):3-11. Review. No abstract available.

PMID:
12125228
41.

Peroxisome proliferator-activated receptor (PPAR) agonists decrease lipoprotein lipase secretion and glycated LDL uptake by human macrophages.

Gbaguidi FG, Chinetti G, Milosavljevic D, Teissier E, Chapman J, Olivecrona G, Fruchart JC, Griglio S, Fruchart-Najib J, Staels B.

FEBS Lett. 2002 Feb 13;512(1-3):85-90.

42.

[PPARs activators and regulation of lipid metabolism, vascular inflammation and atherosclerosis].

Bocher V, Chinetti G, Fruchart JC, Staels B.

Journ Annu Diabetol Hotel Dieu. 2001:23-32. Review. French. No abstract available.

PMID:
11565466
43.

The OSBP-related protein family in humans.

Lehto M, Laitinen S, Chinetti G, Johansson M, Ehnholm C, Staels B, Ikonen E, Olkkonen VM.

J Lipid Res. 2001 Aug;42(8):1203-13.

44.

Peroxisome proliferator-activated receptors (PPARs): nuclear receptors with functions in the vascular wall.

Chinetti G, Fruchart JC, Staels B.

Z Kardiol. 2001;90 Suppl 3:125-32. Review.

PMID:
11374025
45.

Peroxisome proliferator-activated receptors: from transcriptional control to clinical practice.

Torra IP, Chinetti G, Duval C, Fruchart JC, Staels B.

Curr Opin Lipidol. 2001 Jun;12(3):245-54. Review.

PMID:
11353326
46.

PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages.

Neve BP, Corseaux D, Chinetti G, Zawadzki C, Fruchart JC, Duriez P, Staels B, Jude B.

Circulation. 2001 Jan 16;103(2):207-12.

PMID:
11208678
47.

PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway.

Chinetti G, Lestavel S, Bocher V, Remaley AT, Neve B, Torra IP, Teissier E, Minnich A, Jaye M, Duverger N, Brewer HB, Fruchart JC, Clavey V, Staels B.

Nat Med. 2001 Jan;7(1):53-8.

PMID:
11135616
48.

Peroxisome proliferator-activated receptor gamma activators inhibit interleukin-12 production in murine dendritic cells.

Faveeuw C, Fougeray S, Angeli V, Fontaine J, Chinetti G, Gosset P, Delerive P, Maliszewski C, Capron M, Staels B, Moser M, Trottein F.

FEBS Lett. 2000 Dec 15;486(3):261-6.

49.
50.

CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors.

Chinetti G, Gbaguidi FG, Griglio S, Mallat Z, Antonucci M, Poulain P, Chapman J, Fruchart JC, Tedgui A, Najib-Fruchart J, Staels B.

Circulation. 2000 May 23;101(20):2411-7.

PMID:
10821819

Supplemental Content

Loading ...
Support Center